Successful reduced intensity allogeneic stem cell transplantation for systemic AL amyloidosis | Zendy

Imamura Tomoyuki | Zendy; Ogata Masao | Zendy; Kohno Kazuhiro | Zendy; Tomo Tadashi | Zendy; Ohtsuka Eiichi | Zendy; Kikuchi Hiroshi | Zendy; Kadota Junichi | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

Successful reduced intensity allogeneic stem cell transplantation for systemic AL amyloidosis

Author(s) -

Imamura Tomoyuki,

Ogata Masao,

Kohno Kazuhiro,

Tomo Tadashi,

Ohtsuka Eiichi,

Kikuchi Hiroshi,

Kadota Junichi

Publication year - 2006

Publication title -

american journal of hematology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.456

H-Index - 105

eISSN - 1096-8652

pISSN - 0361-8609

DOI - 10.1002/ajh.20544

Subject(s) - al amyloidosis , melphalan , medicine , amyloidosis , transplantation , multiple myeloma , fludarabine , autologous stem cell transplantation , nephrotic syndrome , stem cell , gastroenterology , immunology , chemotherapy , cyclophosphamide , immunoglobulin light chain , genetics , antibody , biology

No established treatments for systemic AL amyloidosis have been determined, and only four reports have described allogeneic stem cell transplantation for this disease. We report the case of a patient with orthostatic hypotension, diarrhea, nephrotic syndrome, and cardiac amyloidosis due to systemic AL amyloidosis. Reduced intensity allogeneic stem cell transplantation (RIST) was performed using a conditioning regimen comprising fludarabine 125 mg/m 2 and melphalan 90 mg/m 2 . Hematologically complete remission and symptomatic improvement were obtained without severe transplantation‐related complications. RIST may thus offer a useful treatment strategy for systemic AL amyloidosis complicated by cardiac amyloidosis. Am. J. Hematol. 81:281–283, 2006. © 2006 Wiley‐Liss, Inc.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research